Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients

Raija Silvennoinen, Veli Kairisto, Tarja-Terttu Pelliniemi, Mervi Putkonen, Pekka Anttila, Marjaana Saily, Anu Sikio, Jorma Opas, Karri Penttila, Taru Kuittinen, Tuomo Honkanen, Tuija Lundan, Vesa Juvonen, Tiina Luukkaala, Kari Remes

Research output: Contribution to journalArticleScientific

Original languageEnglish
JournalBritish Journal of Haematology
Volume160
Issue number4
Pages (from-to)561-564
Number of pages4
ISSN0007-1048
DOIs
Publication statusPublished - Feb 2013
MoE publication typeB1 Journal article

Fields of Science

  • multiple myeloma
  • minimal residual disease
  • molecular genetics
  • bortezomib
  • stem cell transplantation1
  • MINIMAL RESIDUAL DISEASE
  • QUANTITATIVE ASO-PCR
  • 3121 General medicine, internal medicine and other clinical medicine

Cite this